Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

University

NexImmune elects to launch initial public offering
21st January 2021
Robert Lavine
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Bolt Biotherapeutics charges to IPO stage
21st January 2021
Robert Lavine
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
OUI provides fourth quarter update
21st January 2021
Callum Cyrus
Oxford spinouts took in $350m in Q4 and OUI saw strong demand for its consulting services on the back of its covid-19 vaccine success.
Vor Biopharma goes for $150m in IPO
20th January 2021
Robert Lavine
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Karslake slides into UChicago’s Polsky Center
20th January 2021
Callum Cyrus
Christine Karslake is set to lead UChicago’s Polsky Science Ventures unit and will be tasked with setting up a deep tech-focused accelerator.
US universities launch Academic Accelerator
20th January 2021
Callum Cyrus
Indiana University is among four US institutions selected by the US Department of Defense's open national security innovation programme for a new accelerator targeting applied research spinouts.
A1 Group acquires Invenium
20th January 2021
Callum Cyrus
The telecoms group has bought a 51% stake in its portfolio company Invenium, a mobility data analytics company spun out of TU Graz.
Ampacimon procures Diael in acquisition deal
20th January 2021
Callum Cyrus
The insulation breakage measuring device producer is joining Ampacimon having launched out of Polytechnic University of Madrid over ten years ago.

Other News

J-Pharma jacks series D up to $21m
19th January 2021
Liwen-Edison Fu
Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.
Biohaven brings Kleo into the fold
19th January 2021
Thierry Heles
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Atalanta attains series A
18th January 2021
Thierry Heles
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Sana to seek $150m in IPO
18th January 2021
Thierry Heles
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
USF's Sanberg to return to faculty research
15th January 2021
Callum Cyrus
USF's senior vice-president for research and innovation Paul Sanberg will return to being a distinguished professor in neurosurgery and brain repair.
Daily deal net: January 12, 2021
12th January 2021
Callum Cyrus
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Editor's Picks

SETsquared: a global leader continues charging ahead
3rd June 2020
Thierry Heles
The world’s number one incubator has been making a big impact since 2002, having supported more than 4,000 entrepreneurs that have raised more than $2.2bn between them.
It’s not about the money
20th November 2018
Thierry Heles
Lessons from the GUV Summit in Houston, Texas, this month
Big deal: Orchard harvests $200m IPO
5th November 2018
Thierry Heles
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
UCL Technology Fund: an unparalleled approach to commercialisation
8th October 2018
Thierry Heles
Editor Thierry Heles sits down with David Grimm (pictured), manager of the UCL Technology Fund, to find out what makes the fund unique among its UK and international peers.
© 2021 Mawsonia Ltd. All rights reserved.
test reg

Login

Forgot password?

Not yet subscribed?

See your subscription offers here